Last reviewed · How we verify
NCT03395418: ARGOS
Evaluation of the Right Use of Inhaled Therapeutics
trial in COPD Asthma in 50 participants. Completed in 1 November 2019.
1 September 2019
Quick facts
| Lead sponsor | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 December 2017 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 November 2019 |
| Sites | 1 location across France |
Conditions studied
- COPD Asthma — all drugs for COPD Asthma →
Sponsor
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Who can join
18 and older, any sex, with COPD Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Asthma and COPD have a significant impact on public health, affecting about 8 million people in France and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies. The good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences. Thus, education of these patients in the use of devices must be an integral part of medical care. It comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation. The "ARGOS" process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics. Its objective is to provide the answer to what is currently an "unmet need" in the management of asthma and COPD, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03395418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche trials
Trials by the same sponsor.
- NCT05815420 — Home Tele-Monitoring of Non-Invasive Ventilation in COPD Patients in France · unknown
- NCT04010253 — Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patie · NA · completed
- NCT03053011 — Evaluation of the Awakening Capability by a Vibrating Bracelet (BRASSARD) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03395418 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
- Last refreshed: 29 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03395418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing